收藏切换
Validation of compound C19 as a glutaminase C inhibitor
收藏切换
PDF
Ting-ting DU, Yi-chen LIU, Zhi-hui ZHANG, Wei-da WANG, Ming JI*, Xiao-guang CHEN*
Acta Pharmaceutica Sinica | 2022, 57(6) : 1801 - 1807
Less
收藏切换
Acta Pharmaceutica Sinica | 2022, 57(6): 1801-1807
Original Articles
Validation of compound C19 as a glutaminase C inhibitor
Full
Ting-ting DU, Yi-chen LIU, Zhi-hui ZHANG, Wei-da WANG, Ming JI*, Xiao-guang CHEN*
Affiliations
  • State Key Laboratory of Bioactive Substances and Functions of Natural Medicines/Beijing Key Laboratory of Non-clinical Drug Metabolism and PK/PD Study, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China
Published: 2022-06-12 doi: 10.16438/j.0513-4870.2022-0323
Outline
收藏切换

The mitochondrial enzyme glutaminase C (GAC) is highly expressed in a variety of cancer cells, resulting in increased glutamine metabolism and cancer development. Therefore, GAC has become a potential target for anti-tumor drug development. However, current GAC inhibitors shared similar structural characteristics, few new scaffolds were reported. By conducting a prokaryotic Escherichia coli expression system, human GAC protein of high-purity was obtained through lysozyme digestion combined with ultrasound dissociation, and cobalt magnetic beads purification, Moreover, we performed studies to validate interaction between small molecules and GAC protein through thermal shift assay, drug affinity responsive target stability assay, protein crosslinking and GAC enzyme activity detection. Meanwhile, a comprehensive small molecule-protein interaction confirmation and systematic pharmacodynamic study in vitro were carried out on compound C19, which was a reported GAC inhibitor screened from the Enamine database. Results showed that C19 directly bind to GAC protein, disturbed GAC tetramers formation, and inhibited its enzyme catalytic activity. By interfering GAC function, C19 dose-dependently suppressed GAC-mediated glutamine metabolism, reduced glutamate in cancer cells, and thus alleviated A549 and NCI-H1299 non-small cell lung cancer cell growth. Together, C19 was identified as a lead compound, providing a new strategy for the structural design of drugs targeting GAC.

glutaminase C  /  inhibitor  /  C19  /  cancer metabolism  /  glutamine metabolism  /  lead compound
Ting-ting DU, Yi-chen LIU, Zhi-hui ZHANG, Wei-da WANG, Ming JI, Xiao-guang CHEN. Validation of compound C19 as a glutaminase C inhibitor[J]. Acta Pharmaceutica Sinica, 2022 , 57 (6) : 1801 -1807 . DOI: 10.16438/j.0513-4870.2022-0323
Year 2022 volume 57 Issue 6
PDF
192
70
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2022-0323
  • Receive Date:2022-03-14
  • Online Date:2025-12-23
  • Published:2022-06-12
Article Data
Affiliations
History
  • Received:2022-03-14
  • Revised:2022-04-08
Funding
Affiliations
    State Key Laboratory of Bioactive Substances and Functions of Natural Medicines/Beijing Key Laboratory of Non-clinical Drug Metabolism and PK/PD Study, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0323
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT